11/20
04:02 pm
nrix
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia [Yahoo! Finance]
Low
Report
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia [Yahoo! Finance]
11/20
04:00 pm
nrix
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
Low
Report
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
11/17
10:36 am
nrix
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 [Yahoo! Finance]
Medium
Report
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 [Yahoo! Finance]
11/17
10:30 am
nrix
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
Medium
Report
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
11/6
08:07 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
11/5
09:00 am
nrix
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
Low
Report
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
10/31
07:00 am
nrix
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Nurix Therapeutics to Participate in Upcoming Investor Conferences
10/24
07:16 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $35.00 price target on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $35.00 price target on the stock.
10/21
04:00 pm
nrix
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
Low
Report
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
10/21
08:07 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at HC Wainwright from $26.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at HC Wainwright from $26.00 to $30.00. They now have a "buy" rating on the stock.
10/21
08:07 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
10/21
06:22 am
nrix
Nurix Therapeutics' NX-5948 shows promise in Waldenstrom's macroglobulinaemia trial [Yahoo! Finance]
Low
Report
Nurix Therapeutics' NX-5948 shows promise in Waldenstrom's macroglobulinaemia trial [Yahoo! Finance]
10/19
08:00 am
nrix
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia
Low
Report
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia
10/16
04:35 pm
nrix
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur
Medium
Report
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur
10/14
09:52 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target lowered by analysts at Royal Bank of Canada from $27.00 to $26.00. They now have an "outperform" rating on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target lowered by analysts at Royal Bank of Canada from $27.00 to $26.00. They now have an "outperform" rating on the stock.
10/14
09:09 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $31.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $31.00 price target on the stock.
10/14
08:41 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
10/14
02:18 am
nrix
Nurix Therapeutics GAAP EPS of -$0.67 beats by $0.05, revenue of $12.6M misses by $2.04M [Seeking Alpha]
Medium
Report
Nurix Therapeutics GAAP EPS of -$0.67 beats by $0.05, revenue of $12.6M misses by $2.04M [Seeking Alpha]
10/11
04:00 pm
nrix
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Medium
Report
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
10/11
08:07 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $41.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $41.00 price target on the stock.
10/9
07:00 am
nrix
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
Medium
Report
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
10/8
11:13 am
nrix
Nurix: An Attractive Early-Stage Biotech Play [Seeking Alpha]
Low
Report
Nurix: An Attractive Early-Stage Biotech Play [Seeking Alpha]
9/30
07:00 am
nrix
Nurix Therapeutics Announces Presentations at Discovery on Target Conference
Low
Report
Nurix Therapeutics Announces Presentations at Discovery on Target Conference
9/6
09:00 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $26.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $26.00 price target on the stock.
9/6
07:00 am
nrix
Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Low
Report
Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit